Dynamic changes in peripheral blood-targeted miRNA expression profiles in patients with severe traumatic brain injury at high altitude

Si-qing Ma 1*, Xue-xia Xu 1, Zong-zhao He 1, Xin-hui Li 1 and Jun-ming Luo 2

Abstract

Background: The aim of this work is to detect and compare the peripheral blood miRNA expression profiles in patients with severe traumatic brain injury (sTBI) 2, 12, 24, 48, and 72 h after injury at high altitude and to predict the target genes of differential expressed miRNAs.

Methods: Twenty sTBI patients from high-altitude areas were randomly selected according to the inclusion and exclusion criteria and were divided into five groups: the 2-h group, 12-h group, 24-h group, 48-h group, and 72-h group. Peripheral blood miRNA expression profiles were detected using real-time quantitative PCR (qRT-PCR).

Results: The expression levels of miR-18a, miR-203, miR-146a, miR-149, miR-23b, and miR-let-7b in peripheral blood showed significant differences between the 2-h group and the 12-h group. The expression levels of miR-203, miR-146a, miR-149, miR-23b, and miR-let-7f in peripheral blood were up-regulated in the 24-h group. In the 48-h group, the expression levels of miR-181d, miR-29a, and miR-18b were upregulated. In the 72-h group, the expression levels of miR-203, miR-146a, miR-149, miR-23b, and miR-let-7f changed. The main target genes of the differentiation expressed miRNAs were genes that regulate inflammatory responses, apoptosis, and DNA damage/repair.

Conclusions: miRNAs may be involved in the pathogenesis of sTBI by dynamically regulating the target genes that regulate inflammatory responses, apoptosis, and DNA damage/repair pathways.

Keywords: Severe traumatic brain injury, miRNA expression profile, High altitude

Background

Severe traumatic brain injury (sTBI) is the most common accidental injury seen in emergency departments, such as intensive care units (ICUs) [1]. sTBI has a high mortality rate and can lead to different degrees of sensory-motor and cognitive dysfunction in surviving patients [2, 3]. Early diagnosis and accurate assessment of the severity of TBI not only save the lives of patients, but also are critical for the secondary prevention of various complications [4, 5].

MicroRNAs (miRNAs) are a class of endogenous small noncoding single-stranded RNA molecules [6]. Studies have shown that miRNAs can regulate gene expression during the development and progression of diseases under normal physiological conditions, and changes in miRNA expression profiles reflect alterations in physiological and pathological conditions [7]. Similarly, miRNAs play a very important regulatory role in the pathogenesis of sTBI [8]. The Qinghai-Tibet Plateau belongs to a high-altitude area, which can lead to hypoxia. The physiological and clinical manifestations of brain injury in a hypoxic environment can be even more severe. However, few reports have described sTBI at high altitude. Therefore, it is of great significance to explore the mechanisms that aggravate sTBI in high-altitude areas.

In the present study, we dynamically monitored the changes in miRNA expression profiles in the peripheral blood of sTBI patients in the acute phase (within 3 days)
at 2, 12, 24, 48 and 72 h, in Xining, Qinghai Province, China, in an attempt to explore the change in miRNA expression profiles in high altitude locations under a hypoxic environment and provide new evidence for the development of molecular biological treatments and clinical therapeutic strategies for sTBI.

**Methods**

This is a single-center, prospective study. The study protocol was approved by the Ethics Committee of Qinghai People’s Hospital, Xining, China. Written informed consent was obtained from each subject.

sTBI was defined as a Glasgow Coma Scale (GCS) score of 3–8 [9]. The inclusion criteria were as follows: a) sTBI patients receiving treatment in Xining and its surrounding areas (at 2000–3500 m above sea level); b) patients who presented at Qinghai People’s Hospital within 24 h of onset; c) both men and women aged 18–60 years; d) patients who survived within 72 h after injury; and e) patients who understood the objective of the study, and the family members of the patient voluntarily participated in the study by signing the informed consent form. The exclusion criteria were as follows: a) patients with a chronic disease; b) patients with severe comorbidities such as hypovolemic shock and severe thoracic/abdominal injuries; and c) patients younger than 18 years or older than 60 years.

The reagents and instruments used in this study included PAXgene RNA Tubes (BD, USA), miRNeasy Mini kit (Qiagen, USA), NanoDrop 2000 (Thermo, USA), RT2 miRNA PCR Arrays Human Mifinder (Qiagen, USA), 2720 Thermal Cycler (ABI, USA), 7500 Real-Time PCR System (ABI, USA), and a microphotometer (Imple, Germany).

Changes in miRNA expression profiles in 20 eligible sTBI patients 2, 12, 24, 48 and 72 h after admission were detected. For all these patients, 2.9 ml of peripheral blood samples was collected using a PAXgene Blood RNA Tube at the above indicated time points and stored in a ~80°C cryogenic refrigerator for further use.

Dynamic differential miRNA expression levels in peripheral blood were detected in the acute phase. The miRNA expression levels were examined using the RT2 miRNA PCR Arrays Human Mifinder kit. According to the concentration of total miRNA, 100 ng of total miRNA was harvested from each sample to synthesize cDNA with the RT2 Easy First Strand Kit. Then, 100 μl of cDNA template, 1275 μl of 2X RT2 SYBR Green miPCR Master Mix and distillation-distillation H2O (ddH2O) were added to a final volume of 2550 μl. An equal volume of the mixture was dispensed into a 96-well plate. A 25 μl reaction system was prepared, and ABI7500 for PCR assay was used for 40 cycles of amplification. The raw data were exported using the ABI 7500 Sequence Detection System and then uploaded to Qia-gen’s on-line analysis software (http://pcrdatanaalysis.sabiosciences.com/pcr/arrayanalysis.php) to screen out differentially expressed miRNAs.

By using bioinformatic analysis methods, we predicted and analyzed the target genes of the differentially expressed miRNAs and their functions using online tools, including TargetScan, PieTar, and miRanda. Quantitative PCR was used to determine the expression levels of the target genes of differentially expressed miRNAs.

During the miRNA analysis, SA_miRNA_005 was used as an internal control. The differences in target miRNA expression levels between the study samples and the corresponding control were calculated by the 2^{-ΔΔCt} method (expressed as a ratio, and the target miRNA expression level of the control sample was set to 1), where ΔΔCt = ΔCt study sample - ΔCt control sample; ΔCt = Ct miRNA - Ct SA miRNA_005; and 10 Ct is the number of amplification cycles at which a defined threshold of the real-time fluorescence intensity is reached when the amplification shows a logarithmic growth.

**Results**

**General data of sTBI patients**

In total, 20 patients with sTBI were enrolled in this study. There were 12 men and 8 women aged 32–56 years (median: 40 years).

**Quality control of the extracted RNA**

The total RNA concentration was determined using NanoDrop2000C. The A280/A260 ratio was calculated to be 1.8–2.0, and the A260/A230 ratio was > 1.8. RNA integrity was estimated on an Agilent 2100 Bioanalyzer, and the RNA integrity number (RIN) was 10 for all samples. Therefore, the extracted RNA satisfied the requirements for miRNA microarray and real-time quantitative PCR.

**Identification of differential miRNA expression profiles in peripheral blood in sTBI patients**

With the total RNA molecules extracted from all serum samples, a microarray was performed using a miFinder Human Blood PCR Array kit, during which miRNA probes were labeled for neurological impairment. There were more than 84 capture probes for miRNA in the chip. The miRNA expression profiles were analyzed using miFinder miRNA PCR Array software, and the changes in the expression profiles of 84 miRNA molecules at 2, 12, 24, 48, and 72 h in the acute phase were dynamically observed.

The expression levels of 10 miRNAs were upregulated more than 2-fold in the 12-h group compared with those in the 2-h group (Fig. 1). Among them, the expression levels of six miRNAs (miR-18a, miR-203, miR-146a, miR-149, miR-23b, and miR-let-7b) increased more than
10-fold (Fig. 1). The results of the target gene prediction are shown in Table 1.

The expression levels of eight miRNAs in peripheral blood were upregulated more than 2-fold in the 24-h group compared with those in the 2-h group. Among them, the expression levels of five miRNAs (miR-203, miR-146a, miR-149, miR-23b and miR-let-7f) were increased more than 7-fold, and the expression levels of three miRNAs (miR-199a-3p, miR-let-7a, and miR-214) were decreased more than 2-fold (Fig. 2). The results of the target gene prediction are shown in Table 2.

The expression levels of 5 miRNAs in peripheral blood were upregulated more than 2-fold in the 48-h group compared with those in the 2-h group. Among them, the expression levels of miR-181d increased more than 8-fold, and the expression levels of two miRNAs (miR-181C and miR-214) decreased more than 2-fold (Fig. 3). The results of the target gene prediction are shown in Table 3.

The expression levels of seven miRNAs in peripheral blood were upregulated more than 2-fold in the 72-h group compared with those in the 2-h group. Among them, the expression levels of five miRNAs (miR-203, miR-146a, miR-149, miR-23b and miR-let-7f) increased more than 5-fold, and the expression level of one miRNA (miR-199a-3p) decreased more than 2-fold (Fig. 4). The results of the target gene prediction are shown in Table 4.

![Fig. 1](image-url) Changes in miRNA expression profiles in peripheral blood in the 12-h group compared with 2-h group

| Table 1 | Main target genes of the differentially expressed miRNAs in the 12-h group compared with 2-h group |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| **Upregulated** | **Name of miRNA** | **Predicted target genes** |
| miR-18a | Neural precursor cell expressed; developmentally regulated protein 9; glycine receptor |
| miR-203 | 4/all family, member 4; elongation factor RNA polymerase II, 2 |
| miR-146a | Zinc finger protein 826; tumor necrosis factor receptor-associated factor 6 (TRAF6) |
| miR-149 | AP2-associated protein kinase 1; PH domain and leucine-rich repeat protein phosphatase |
| miR-23b | Zinc finger protein 138; fucosyltransferase (alpha-fucosyltransferase (1,3) 9 |
| miR-let-7f | High mobility group AT-hook 2; chromosome 14 open reading frame 28 |
| miR-let-7b | High mobility group AT-hook 2; chromosome 14 open reading frame 28 |
| miR-132 | Transmembrane protein 106B; zinc finger protein 516 |
| miR-128a | Inflammatory pathways |
| miR-372 | Involved in DNA damage response |
| **Downregulated** | | |
| miR-let-7a | Angiogenesis in rheumatoid arthritis via HIF-1α activation |
| miR-214 | NMDA receptor-regulated 2; k-opioid receptor |
| miR-199a-3p | Cadherin EGF LAG seven pass G-Type receptor 2; SH3 domain-containing GRB2-like endophilin B1 |
Multiple miRNAs showed various changes in the peripheral blood in the 12-h, 24-h, 48-h, and 72-h groups compared with those in the 2-h group. The possible target genes of the differentially expressed miRNAs were predicted using TargetScan, miRanda, and PicTar software. It was found that, the neurological impairment following sTBI was mainly related to cell proliferation, apoptosis, differentiation, the inflammatory response, and collagen formation.

Discussion

The sequelae of sTBI are complex and diverse [10, 11]. It has been recognized that the development of symptoms in the acute stage of TBI is associated with the following factors: inflammatory responses (e.g., serum response factors) [12], immune responses, vascular responses, and tumor necrosis factor [13]; DNA damage and repair; apoptosis; differential expression of cell growth factors; and pathways involving transcriptional regulatory proteins [14]. Research on miRNA expression profiles following TBI has suggested that miRNAs play a key role in this process [15]. A bioinformatics analysis showed that changes in miRNA expression affect the pathophysiological processes of brain injury, including secondary injury related to the inflammatory response and apoptosis [16]. Many studies on miRNA expression levels in patients with TBI have confirmed the changes in serum miRNA expression profiles in TBI patients [17].

In the present study, miRNA microarray and fluorescence-based quantitative real-time PCR were applied to detect and analyze the dynamic changes in miRNA expression levels in the peripheral blood of sTBI patients at high altitude. Our results showed that the expression levels of miR-18a, miR-203, miR-146a, miR-149, miR-23b, and miR-let-7b in peripheral blood increased more than 10-fold in the 12-h

Table 2

| Change in miRNA expression | Name of miRNA | Predicted target genes |
|----------------------------|---------------|------------------------|
| Upregulated                | miR-203       | 4-all family, member 4; elongation factor RNA polymerase II, 2 |
|                            | miR-146a      | Zinc finger protein 826; tumor necrosis factor receptor-associated factor 6 (TRAF6) |
|                            | miR-149       | AP2-associated protein kinase 1; PH domain and leucine-rich repeat protein phosphatase |
|                            | miR-23b       | Zinc finger protein 138; fucosyltransferase (alpha-fucosyltransferase (1,3) 9 |
|                            | miR-let-7f    | High mobility group AT-hook 2; chromosome 14 open reading frame 28 |
|                            | miR-363       | Protects cardiomyocytes against hypoxia-induced apoptosis through regulation of Notch signaling |
|                            | miR-29a       | ATPase family AAA domain-containing protein 2B; peptidase inhibitor 15 |
|                            | miR-122       | Chloride channel 4; regulatory factor X-associated protein |
| Downregulated              | miR-199a-3p   | Cadherin EGF LAG seven pass G-type receptor 2; SH3 domain-containing GRB2-like endophilin B1 |
|                            | miR-let-7a    | Angiogenesis in rheumatoid arthritis via HIF-1α activation |
|                            | miR-214       | NMDA receptor-regulated 2; κ-opioid receptor |
group compared with that of the 2-h group. These miRNA molecules might also be involved in the damage and repair of tumor necrosis factor (TNF) and DNA. In addition, the expression levels of miR-203, miR-146a, miR-149, miR-23b and miR-let-7f in peripheral blood increased more than 10-fold in the 24-h group. Similarly, both miR-203 and miR-let-7 were highly expressed in the acute phase, indicating that the inflammatory response was involved in the pathophysiological process of sTBI in high-altitude areas. Furthermore, the expression levels of miR-181d, miR-29a, and miR-18b increased more than 5-fold 48 h after the onset of sTBI at high altitude, and the expression levels of miR-203, miR-146a, and miR-149 increased over 5-fold after 72 h. Thus, the changes in the inflammatory response in the expression levels of miRNA molecules became mild compared with the acute phase response, and the differential genes gradually weakened, suggesting that the inflammatory response tended to be attenuated as the disease progressed. These dynamic changes in the miRNA expression profiles have provided important evidence to better understand the pathophysiological processes of sTBI at high altitude.

MiRNA is an important factor regulating inflammation. Yang et al. [18] suggested that microglia-mediated inflammation plays an important role in ischemic brain injury, while miR-203 negatively regulates ischemia-induced microglia activation by targeting MyD88. Through negative feedback, enforced expression of miR-203 silencing inhibits downstream NF-kappa beta signaling and microglia activation, thereby alleviating neuronal injury. The miR-let-7b mimic reduces the expression of interleukin 6 (IL6) and TNF in monocytes and the expression of SERPINE1 in LPS-activated macrophages [19], which plays an anti-inflammatory role. Studies by Kumar et al. [20] showed that miR-let-7f overexpression reduced Mtb (Mycobacterium tuberculosis) survival and increased the production of cytokines such as TNF and interleukin 1 beta (IL-1β). Furthermore, miR-let-7f and its target A20 regulated the immune response to Mtb and controlled the bacterial load [20]. The role of miRNA is associated with TBI, and Sun et al. [21] found that overexpression of miR-23b conferred better neuroprotective effects after TBI by decreasing lesion volume, alleviating brain edema, inhibiting neuronal apoptosis and attenuating long-term neurological deficits. In addition, experimental animal

| Table 3 Main target genes of the differentially expressed miRNAs in the 48-h group compared with 2-h group |
|-------------------------------------------------------------------------------------------------|
| **Change in miRNA expression** | **Name of miRNA** | **Predicted target genes** |
| Upregulated | miR-181d | Zinc finger protein 594; zinc finger protein 440 |
| | miR-29a | ATPase family AAA domain-containing protein 2B; peptidase inhibitor 15 |
| | miR-18b | Neural precursor cells expressed; developmentally regulated protein 9; glycine receptor |
| | miR-132 | Transmembrane protein 106B; zinc finger protein 516 |
| | miR-let-7b | High mobility group AT-hook 2; chromosome 14 open reading frame 28 |
| Downregulated | miR-181c | Modulates the proliferation, migration, and invasion of neuroblastoma cells by targeting Smad7 |
| | miR-214 | NMDA receptor-regulated 2; κ-opioid receptor |
studies have tested specific microRNAs such as miR-23b as biomarkers and therapeutic targets in cases of moderate and mild TBI [22]. These studies demonstrate, to varying degrees, the relationship between miRNAs found in this study and TBI or inflammation, enhancing the reliability of this study. Redell et al. [23] suggested that miR-16, miR-92a, and miR-765 were ideal biomarkers for severe brain injury, which is not entirely consistent with our findings. The possible explanation is that our subjects were sTBI patients from a high-altitude area.

**Conclusions**

In summary, we observed dynamic differences in miRNA expression profiles in the peripheral blood of sTBI patients in the acute phase in a high-altitude area. Through the prediction of the main target genes of differentially expressed miRNAs, we could speculate about the pathophysiological evolution of sTBI and identify the miRNA expression levels related to the central nervous system in the acute phase of sTBI as well as miRNA expression levels at high altitude. Early interventions with drugs or other clinical therapies should be administered to achieve precise treatment, improve therapeutic efficacy, and reduce mortality and disability.

**Abbreviations**

GCS: Glasgow Coma Scale; ICU: Intensive care unit; miRNAs: MicroRNAs; qRT-PCR: real-time quantitative PCR; RIN: RNA integrity number; sTBI: severe traumatic brain injury

**Acknowledgements**

This work was supported by the Qinghai Provincial Agricultural Science and Technology Achievements Transformation and Extension Project (2013-N-531). This work has been approved by the ethnic group of Qinghai Provincial People’s Hospital.

**Funding**

This work was supported by the Qinghai Provincial Agricultural Science and Technology Achievements Transformation and Extension Project (2013-N-531).

**Availability of data and materials**

The datasets generated and analyzed during the current study are not publicly available.

**Authors’ contributions**

SQM designed the experiments. XXX, ZZH and XHL performed the experiments and data analysis. SQM and JML wrote the manuscript. SQM supervised the project. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Written informed consent was obtained from each patient prior to enrollment, and the present study was approved by the ethics committee of Qinghai Province People’s Hospital.

Consent for publication
Not applicable.

Competing interests
All authors have read and approved the final manuscript and declare that they have no competing interests.

Author details
1Department of Intensive Care Unit, Qinghai Provincial People’s Hospital, Xining 810007, China. 2Department of Pathology, Qinghai Provincial People’s Hospital, Xining 810007, China.

Received: 26 November 2018 Accepted: 7 April 2019
Published online: 30 April 2019

References
1. Amantini A, Amadori A, Fossi S. Evoked potentials in the ICU. Eur J Anaesthesiol Suppl. 2008;42(1):196–202.
2. Amantini A, Carrai R, Lori S, Peris A, Amadori A, Pinto F, et al. Neurophysiological monitoring in adult and pediatric intensive care. Minerva Anestesiol. 2012;78(9):1067–75.
3. Bahloul M, Chelly H, Chaari A, Chabchoub I, Haddar S, Herquefi L, et al. Isolated traumatic head injury in children: analysis of 276 observations. J Emerg Trauma Shock. 2011;4:29–36.
4. Amdt DH, Lerner JT, Matsumoto JH, Madikians A, Yudovin S, Valino H, et al. MyD88 in ischemia. Mol Immunol. 2015;65:293–9.
5. Badjatia N. Fever control in the neuro-ICU: why, who, and when? Curr Opin Anaesthesiol Suppl. 2008;42(1):196–202.
6. Balakathiresan N, Bhomia M, Chandran R, Chakvo M, McCarron RM, Maheshwari RK. Microrna let-7i is a promising serum biomarker for blast-induced traumatic brain injury. J Neurotrauma. 2012;29(7):1379–87.
7. Ballestros MA, López-Hoyos M, Muñoz P, Marin MJ, Mihombres E. Apoptosis of neuronal cells induced by serum of patients with acute brain injury: a new in vitro prognostic model. Intensive Care Med. 2007;33(1):58–65.
8. Achaarya SS. Serum microRNAs are early indicators of survival after radiation-induced hematopoietic injury. Sci Transl Med. 2015;7:287ra69.
9. Bucy PC. Neurosurgical critical care. Surg Neurol. 1987;1(1):80–8.
10. Berardino M, Morrone O, Sciacca PF, Rosato R, Ciccone G, Massaro F. MicroRNA-let-7 modulates the immune response to mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-κB pathway. Cell Host Microbe. 2015;17(3):345–56.
11. Ballesteros MA, López-Hoyos M, Muñoz P, Marin MJ, Mihombres E. Apoptosis of neuronal cells induced by serum of patients with acute brain injury: a new in vitro prognostic model. Intensive Care Med. 2007;33(1):58–65.
12. Bahnson D, Lerner JT, Matsumoto JH, Madikians A, Yudovin S, Valino H, et al. MyD88 in ischemia. Mol Immunol. 2015;65:293–9.
13. Bahloul M, Chelly H, Chaari A, Chabchoub I, Haddar S, Herquefi L, et al. Isolated traumatic head injury in children: analysis of 276 observations. J Emerg Trauma Shock. 2011;4:29–36.
14. Amdt DH, Lerner JT, Matsumoto JH, Madikians A, Yudovin S, Valino H, et al. MyD88 in ischemia. Mol Immunol. 2015;65:293–9.
15. Badjatia N. Fever control in the neuro-ICU: why, who, and when? Curr Opin Anaesthesiol Suppl. 2008;42(1):196–202.
16. Balakathiresan N, Bhomia M, Chandran R, Chakvo M, McCarron RM, Maheshwari RK. Microrna let-7i is a promising serum biomarker for blast-induced traumatic brain injury. J Neurotrauma. 2012;29(7):1379–87.
17. Ballestros MA, López-Hoyos M, Muñoz P, Marin MJ, Mihombres E. Apoptosis of neuronal cells induced by serum of patients with acute brain injury: a new in vitro prognostic model. Intensive Care Med. 2007;33(1):58–65.
18. Achaarya SS. Serum microRNAs are early indicators of survival after radiation-induced hematopoietic injury. Sci Transl Med. 2015;7:287ra69.
19. Bucy PC. Neurosurgical critical care. Surg Neurol. 1987;1(1):80–8.
20. Berardino M, Morrone O, Sciacca PF, Rosato R, Ciccone G, Massaro F. MicroRNA-let-7 modulates the immune response to mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-κB pathway. Cell Host Microbe. 2015;17(3):345–56.
21. Bahnson D, Lerner JT, Matsumoto JH, Madikians A, Yudovin S, Valino H, et al. MyD88 in ischemia. Mol Immunol. 2015;65:293–9.
22. Bahloul M, Chelly H, Chaari A, Chabchoub I, Haddar S, Herquefi L, et al. Isolated traumatic head injury in children: analysis of 276 observations. J Emerg Trauma Shock. 2011;4:29–36.
23. Redell JB, Moore AN, Ward NH 3rd, Hergenroeder GW, Dash PK. Human traumatic brain injury alters plasma microrna levels. J Neurotrauma. 2010;27(12):2147–56.

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

BMC